Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Molecular Medicine
  4. Fast Track Articles
  5. Fast Track Article
image of The AMPK/cAMP Metabolic Signaling Axis as a Possible Therapeutic Target for Diabetes

Abstract

Diabetes is a complex disease, despite the availability of numerous treatments, its progression and complications can only be mitigated and managed to a certain extent. After the onset, diabetes cannot be reversed. Its global expansion makes it challenging for governments to control the considerable costs of treating people with diabetes. Many studies have been carried out by widely recognized pharmaceutical companies that are considering the development of new drugs for diabetic treatments. Diets, sedentary habits, and lifestyles that are currently prevalent have an enormous influence on the global spread of diabetes. The tools available to clinicians for therapy do not solve the problem. It is known that a patient, when diagnosed, would already have had diabetes for more than three years. Studies on diabetes signaling consider the effects of hyperglycemia but also highlight the roles of insulin receptor activation and resistance.

Understanding the intricate signaling network and its interactions with hyperglycemia-induced pathways is crucial. In this context, the cyclic AMP/AMPK axis emerges as a promising therapeutic target for diabetes. However, there is a noticeable lack of literature exploring the metabolic network induced by hyperglycemia and its interconnected pathways. Therefore, investigating the cyclic cAMP/AMPK axis could provide valuable insights, given its complex connections with various metabolic pathways. This mini-review aims to delve into the metabolic signaling of the AMPK/cAMP axis in the context of diabetes, highlighting its metabolic interactions and potential implications.

© 2024 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cmm/10.2174/0115665240298668240528110159
2024-09-09
2024-11-26

  • From This Site

    /content/journals/cmm/10.2174/0115665240298668240528110159
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Kenny H.C. Abel E.D. Heart failure in type 2 diabetes mellitus. Circ. Res. 2019 124 1 121 141 10.1161/CIRCRESAHA.118.311371 30605420
    [Google Scholar]
  2. Singh R. Epigenetic modification and therapeutic targets of diabetes mellitus. Biosci. Rep. 2020 40 9 BSR20202160
    [Google Scholar]
  3. Beckman J.A. Creager M.A. Libby P.J.J. Diabetes and atherosclerosis: Epidemiology, pathophysiology, and management. JAMA 2002 287 19 2570 2581
    [Google Scholar]
  4. Ziyadeh F.N. Sharma K. Overview: Combating diabetic nephropathy. J. Am. Soc. Nephrol. 2003 14 5 1355 1357
    [Google Scholar]
  5. Fong D.S. Diabetic retinopathy. Diabetes Care 2003 26 1 S99 S102
    [Google Scholar]
  6. Natarajan R. Nadler J. biology, Lipid inflammatory mediators in diabetic vascular disease. Arterioscler. Thromb. Vasc. Biol. 2004 24 9 1542 1548
    [Google Scholar]
  7. Vincent A.M. Biology of diabetic neuropathy. Handb. Clin. Neurol. 2013 115 591 601
    [Google Scholar]
  8. Forbes J.M. Cooper M. Mechanisms of diabetic complications. Physiol. Rev. 2013 93 1 137 188
    [Google Scholar]
  9. Shati A.A. Alfaifi M.Y. Salidroside protects against diabetes mellitus‐induced kidney injury and renal fibrosis by attenuating TGF‐β1 and Wnt1/3a/β‐catenin signalling. Clin. Exp. Pharmacol. Physiol. 2020 47 10 1692 1704 10.1111/1440‑1681.13355 32472701
    [Google Scholar]
  10. Rezaeepoor M. Hoseini-Aghdam M. Sheikh V. Eftekharian M.M. Behzad M. evaluation of interleukin-23 and JAKs/STATs/SOCSs/ROR- γt expression in type 2 diabetes mellitus patients treated with or without sitagliptin. J. Interferon Cytokine Res. 2020 40 11 515 523 10.1089/jir.2020.0113 33136467
    [Google Scholar]
  11. Alfaifi M. Verma A.K. Alshahrani M.Y. Assessment of cell-free long non-coding RNA-H19 and miRNA- 29a, miRNA-29b expression and severity of diabetes. Diabetes Metab. Syndr. Obes. 2020 13 3727 3737 10.2147/DMSO.S273586 33116722
    [Google Scholar]
  12. Tu C. Wang L. Tao H. Gu L. Zhu S. Chen X. Expression of miR-409-5p in gestational diabetes mellitus and its relationship with insulin resistance. Exp. Ther. Med. 2020 20 4 3324 3329 10.3892/etm.2020.9049 32855704
    [Google Scholar]
  13. Weale C.J. Matshazi D.M. Davids S.F.G. Circulating miR-30a-5p and miR-182-5p in Prediabetes and Screen-Detected Diabetes Mellitus. Diabetes Metab. Syndr. Obes. 2020 13 5037 5047 10.2147/DMSO.S286081 33376373
    [Google Scholar]
  14. Nogueira-Machado J.A. Chaves M.M. From hyperglycemia to AGE-RAGE interaction on the cell surface: A dangerous metabolic route for diabetic patients. Expert Opin. Ther. Targets 2008 12 7 871 882 10.1517/14728222.12.7.871 18554155
    [Google Scholar]
  15. Volpe C.M.O. Villar-Delfino P.H. dos Anjos P.M.F. Nogueira-Machado J.A. Cellular death, reactive oxygen species (ROS) and diabetic complications. Cell Death Dis. 2018 9 2 119 10.1038/s41419‑017‑0135‑z 29371661
    [Google Scholar]
  16. Cool B. Zinker B. Chiou W. Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome. Cell Metab. 2006 3 6 403 416 10.1016/j.cmet.2006.05.005 16753576
    [Google Scholar]
  17. DeStefano M.A. Jacinto E. Regulation of insulin receptor substrate-1 by mTORC2 (mammalian target of rapamycin complex 2). Biochem. Soc. Trans. 2013 41 4 896 901 10.1042/BST20130018 23863152
    [Google Scholar]
  18. Peng M. Fu Y. Wu C. Zhang Y. Ren H. Zhou S. Signaling pathways related to oxidative stress in diabetic cardiomyopathy. Front. Endocrinol. 2022 13 907757 10.3389/fendo.2022.907757 35784531
    [Google Scholar]
  19. Giordanetto F. Karis D. Direct AMP-activated protein kinase activators: A review of evidence from the patent literature. Expert Opin. Ther. Pat. 2012 22 1467 1477
    [Google Scholar]
  20. Xiao B. Sanders M.J. Carmena D. Structural basis of AMPK regulation by small molecule activators. Nat. Commun. 2013 4 1 3017 10.1038/ncomms4017 24352254
    [Google Scholar]
  21. Shamshoum H. Vlavcheski F. MacPherson R.E.K. Tsiani E. Rosemary extract activates AMPK, inhibits mTOR and attenuates the high glucose and high insulin-induced muscle cell insulin resistance. Appl. Physiol. Nutr. Metab. 2021 46 7 819 827 10.1139/apnm‑2020‑0592 33471600
    [Google Scholar]
  22. Zhang Y. Zhu Z. Zhai W. Bi Y. Yin Y. Zhang W. Expression and purification of asprosin in Pichia pastoris and investigation of its increase glucose uptake activity in skeletal muscle through activation of AMPK. Enzyme Microb. Technol. 2021 144 109737 10.1016/j.enzmictec.2020.109737 33541572
    [Google Scholar]
  23. Prabha B. Sini S. Sherin D.R. Promalabaricone B from Myristica fatua Houtt. seeds demonstrate antidiabetic potential by modulating glucose uptake via the upregulation of AMPK in L6 myotubes. Nat. Prod. Res. 2021 35 5 867 872 10.1080/14786419.2019.1607852 31104493
    [Google Scholar]
  24. Zhao M. Qin J. Shen W. Wu A. Bilobalide enhances AMPK activity to improve liver injury and metabolic disorders in STZ-induced diabetes in immature rats via regulating HMGB1/TLR4/NF-κB signaling pathway. BioMed Res. Int. 2021 2021 1 11 10.1155/2021/8835408 33959665
    [Google Scholar]
  25. Su W.Y. Li Y. Chen X. Ginsenoside Rh1 improves type 2 diabetic nephropathy through AMPK/PI3K/Akt-mediated inflammation and apoptosis signaling pathway. Am. J. Chin. Med. 2021 49 5 1215 1233 10.1142/S0192415X21500580 34049473
    [Google Scholar]
  26. Entezari M. Hashemi D. Taheriazam A. AMPK signaling in diabetes mellitus, insulin resistance and diabetic complications: A pre-clinical and clinical investigation. Biomed. Pharmacother. 2022 146 112563 10.1016/j.biopha.2021.112563 35062059
    [Google Scholar]
  27. Zaccolo M. Zerio A. Lobo M.J. Subcellular organization of the camp signaling pathway. Pharmacol. Rev. 2021 73 1 278 309 10.1124/pharmrev.120.000086 33334857
    [Google Scholar]
  28. Feehan K.T. Gilroy D.W. Is resolution the end of inflammation? Trends Mol. Med. 2019 25 3 198 214 10.1016/j.molmed.2019.01.006 30795972
    [Google Scholar]
  29. Tavares L.P. Negreiros-Lima G.L. Lima K.M. Blame the signaling: Role of cAMP for the resolution of inflammation. Pharmacol. Res. 2020 159 105030 10.1016/j.phrs.2020.105030 32562817
    [Google Scholar]
  30. Salminen A. Hyttinen J.M.T. Kaarniranta K. AMP-activated protein kinase inhibits NF-κB signaling and inflammation: Impact on healthspan and lifespan. J. Mol. Med. 2011 89 7 667 676 10.1007/s00109‑011‑0748‑0 21431325
    [Google Scholar]
  31. Neumann M. Grieshammer T. Chuvpilo S. RelA/p65 is a molecular target for the immunosuppressive action of protein kinase A. EMBO J. 1995 14 9 1991 2004 10.1002/j.1460‑2075.1995.tb07191.x 7744006
    [Google Scholar]
  32. Kamthong P.J. Wu M. Inhibitor of nuclear factor-κB induction by cAMP antagonizes interleukin-1-induced human macrophage-colony-stimulating-factor expression. Biochem. J. 2001 356 2 525 530 10.1042/bj3560525 11368781
    [Google Scholar]
  33. Wall E.A. Zavzavadjian J.R. Chang M.S. Suppression of LPS-induced TNF-alpha production in macrophages by cAMP is mediated by PKA-AKAP95-p105. Sci. Signal. 2009 2 75 ra28 10.1126/scisignal.2000202 19531803
    [Google Scholar]
  34. Scheibner K.A. Boodoo S. Collins S. The adenosine a2a receptor inhibits matrix-induced inflammation in a novel fashion. Am. J. Respir. Cell Mol. Biol. 2009 40 3 251 259 10.1165/rcmb.2008‑0168OC 18703794
    [Google Scholar]
  35. Chen Y. Zheng Y. Liu L. Adiponectin inhibits TNF-α-activated PAI-1 expression via the cAMP-PKA-AMPK-NF-κB axis in human umbilical vein endothelial cells. Cell. Physiol. Biochem. 2017 42 6 2342 2352 10.1159/000480006 28848135
    [Google Scholar]
  36. Wei R. Ma S. Wang C. Exenatide exerts direct protective effects on endothelial cells through the AMPK/Akt/ eNOS pathway in a GLP-1 receptor-dependent manner. Am. J. Physiol. Endocrinol. Metab. 2016 310 11 E947 E957 10.1152/ajpendo.00400.2015 27072494
    [Google Scholar]
  37. Holz G.G. Epac: A new cAMP-binding protein in support of glucagon-like peptide-1 receptor-mediated signal trans-duction in the pancreatic beta-cell. Diabetes 2004 53 1 5 13 10.2337/diabetes.53.1.5 14693691
    [Google Scholar]
  38. He L. Chang E. Peng J. Activation of the cAMP-PKA pathway antagonizes metformin suppression of hepatic glucose production. J. Biol. Chem. 2016 291 20 10562 10570 10.1074/jbc.M116.719666 27002150
    [Google Scholar]
  39. Zhang T. Wang S. Lin Y. Acetylation negatively regulates glycogen phosphorylase by recruiting protein phosphatase 1. Cell Metab. 2012 15 1 75 87 10.1016/j.cmet.2011.12.005 22225877
    [Google Scholar]
  40. Jones B. The therapeutic potential of GLP-1 receptor biased agonism. Br. J. Pharmacol. 2022 179 4 492 510 33880754
    [Google Scholar]
  41. Ma Z.G. Yuan Y.P. Xu S.C. CTRP3 attenuates cardiac dysfunction, inflammation, oxidative stress and cell death in diabetic cardiomyopathy in rats. Diabetologia 2017 60 6 1126 1137 10.1007/s00125‑017‑4232‑4 28258411
    [Google Scholar]
  42. He L. Sabet A. Djedjos S. Metformin and insulin suppress hepatic gluconeogenesis through phosphorylation of CREB binding protein. Cell 2009 137 4 635 646 10.1016/j.cell.2009.03.016 19450513
    [Google Scholar]
  43. Zhao A.Z. Shinohara M.M. Huang D. Leptin induces insulin-like signaling that antagonizes cAMP elevation by glucagon in hepatocytes. J. Biol. Chem. 2000 275 15 11348 11354 10.1074/jbc.275.15.11348 10753948
    [Google Scholar]
  44. Pickup J.C. Mattock M.B. Chusney G.D. Burt D. NIDDM as a disease of the innate immune system: Association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 1997 40 11 1286 1292 10.1007/s001250050822 9389420
    [Google Scholar]
  45. Pickup J.C. Crook M.A. Is Type II diabetes mellitus a disease of the innate immune system? Diabetologia 1998 41 10 1241 1248 10.1007/s001250051058 9794114
    [Google Scholar]
  46. Tomás E. Lin Y.S. Dagher Z. Hyperglycemia and insulin resistance: Possible mechanisms. Ann. N. Y. Acad. Sci. 2002 967 1 43 51 10.1111/j.1749‑6632.2002.tb04262.x 12079834
    [Google Scholar]
  47. Srivastava A. High glucose-induced activation of protein kinase signaling pathways in vascular smooth muscle cells: A potential role in the pathogenesis of vascular dysfunction in diabetes (Review). Int. J. Mol. Med. 2002 9 1 85 89 10.3892/ijmm.9.1.85 11745003
    [Google Scholar]
  48. Saitoh M. Nishitoh H. Fujii M. Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. EMBO J. 1998 17 9 2596 2606 10.1093/emboj/17.9.2596 9564042
    [Google Scholar]
  49. Nogueira-Machado J.A. Lima e Silva F.C. Cunha E.P. Modulation of the production of Reactive Oxygen Species (ROS) by cAMP-elevating agents in granulocytes from diabetic patients: An Akt/PKB-dependent phenomenon. Diabetes Metab. 2006 32 4 331 335 10.1016/S1262‑3636(07)70287‑2 16977260
    [Google Scholar]
  50. Jiang Y. Steinle J.J. Epac1 requires AMPK phosphorylation to regulate HMGB1 in the retinal vasculature. Invest. Ophthalmol. Vis. Sci. 2020 61 11 33 10.1167/iovs.61.11.33 32940662
    [Google Scholar]
  51. Nogueira-Machado J.A. Lima E. Silva F.C. Medina L.O. Costa D.C. Chaves M.M. Modulation of the reactive oxygen species (ROS) generation mediated by cyclic AMP-elevating agents or interleukin 10 in granulocytes from type 2 diabetic patients (NIDDM): A PKA-independent phenomenon. Diabetes Metab. 2003 29 5 533 537 10.1016/S1262‑3636(07)70068‑X 14631331
    [Google Scholar]
  52. Isoni C.A. Borges É.A. Veloso C.A. Mattos R.T. Chaves M.M. Nogueira-Machado J.A. cAMP activates the generation of reactive oxygen species and inhibits the secretion of IL-6 in peripheral blood mononuclear cells from type 2 diabetic patients. Oxid. Med. Cell. Longev. 2009 2 5 317 321 10.4161/oxim.2.5.9657 20716919
    [Google Scholar]
  53. Yarwood S.J. Special issue on “new advances in cyclic amp signalling”—an editorial overview. Cells 2020 9 10 2274 10.3390/cells9102274 33053803
    [Google Scholar]
/content/journals/cmm/10.2174/0115665240298668240528110159
Loading
The AMPK/cAMP Metabolic Signaling Axis as a Possible Therapeutic Target for Diabetes
Bentham Science Publishers ; https://doi.org/10.2174/0115665240298668240528110159
/content/journals/cmm/10.2174/0115665240298668240528110159
/content/journals/cmm/10.2174/0115665240298668240528110159
Loading

Data & Media loading...


  • Article Type:     Review Article
Keywords: AD ; metabolic signaling ; AMPK ; hyperglycemia ; cAMP ; Diabetes mellitus

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test